Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer.
Yi SY, Park YS, Kim HS, Jun HJ, Kim KH, Chang MH, Park MJ, Uhm JE, Lee J, Park SH, Park JO, Lee JK, Lee KT, Lim HY, Kang WK.
Yi SY, et al.
Cancer Chemother Pharmacol. 2009 May;63(6):1141-5. doi: 10.1007/s00280-008-0839-y. Epub 2008 Oct 7.
Cancer Chemother Pharmacol. 2009.
PMID: 18839175
Clinical Trial.